Project Details
Projekt Print View

TRR 19:  Inflammatory Cardiomyopathy - Molecular Pathogenesis and Therapy

Subject Area Medicine
Biology
Term from 2004 to 2013
Project identifier Deutsche Forschungsgemeinschaft (DFG) - Project number 5486135
 
Area of Research is the Dilatated Cardiomyopathy (DCM), a heart muscle disease characterised by left and right ventricular dysfunction and dilatation. DCM is alongside coronary heart disease (CHD) the most frequent cause of heart failure. About 30% of patients develop heart failure as a consequence of DCM. In Germany about 500 000 patients suffer from DCM. Because of the high clinical relevance of the disorder there is an urgent need to develop new diagnostic and therapeutic procedures. The importance of DCM is also illustrated by the fact that alongside CHD it constitutes the main indication for heart transplantation (HTX).
According to recent research myocardial inflammation and/or viral infection (= Inflammatory Cardio-myopathy, DCMi) is the most frequent cause of DCM. Despite new pharmacotherapeutic approaches towards heart failure the 5-year-mortality of DCM is still higher than 50%, but currently there are no generally accepted therapeutic guidelines for DCMi. For most patients HTX is the only accepted palliative thera-peutic option beyond symptomatic heart failure therapy.
The general research goals in the subareas A-C are:
-- elucidation of structural determinants of DCMi at the cellular and molecular level
-- characterisation of virus-host-interactions and their relevance for the course of DCMi
-- development of new experimental and clinical therapeutic approaches building upon new findings from A and B
Goals in detail:
-- elucidation of exogenous and genetic determinants for the highly variable susceptibility for myocardial virus infections
-- detailed understanding of the rapid and potentially reversible "remodelling" of the myocardium during viral infections
-- elucidation of the immune mechanisms which, dependent on viral and host-specific pathogenicity factors, determine the course of the disease
-- development, evaluation, and possible clinical implementation of new experimental and clinical therapeutic procedures
-- further development of novel therapeutic approaches which may have therapeutic implications for cardiovascular medicine beyond the specific target disease of DCMi (RNA-based and gene therapeutic strategies etc.)
-- development of new genetic animal models (conditional tissue-specific knockouts etc.) for the evaluation of new therapeutic strategies and other purposes
DFG Programme CRC/Transregios

Completed projects

Applicant Institution shared FU Berlin and HU Berlin through:
Charité - Universitätsmedizin Berlin
 
 

Additional Information

Textvergrößerung und Kontrastanpassung